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Abstract
Background: We explored the heterogeneity of philadelphia chromosome-positive acute
lymphoblastic leukemia (Ph1-ALL) in a study of the effect of early features on prognosis in children.
Here we report the long-term results of the FRALLE 93 study conducted in the era before the use
of tyrosine kinase inhibitors.
Methods: Between 1993 and 1999, 36 children with Ph1-ALL were enrolled into the FRALLE 93
protocol. After conventional four-drug induction, children were stratified by availability of an HLA-
matched sibling.
Results: Complete remission (CR) was observed in 26 children (72%), of which 13 underwent
allogeneic bone marrow transplantation (BMT). Thirty-one children were good responders to
prednisone, defined on day 8, and 21 were good responders to chemotherapy, defined by day-21
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BMC Cancer 2009, 9:14 http://www.biomedcentral.com/1471-2407/9/14bone marrow (M1). Overall five-year disease-free survival (DFS) was 42 ± 9.7%. Based on
multivariate analysis, two groups showed marked differences in five-year outcome: children with
age<10, leukocyte count <100,000/mm3 and day-21 M1 marrow had a more favorable prognosis
(14 pts: 100% CR, event free survival [EFS]: 57%, overall survival [OS]: 79%), than the high-risk
group (22 patients: 55% CR, EFS: 18%, OS: 27%) (p < 0.005). We also observed a non statistically
significant difference (p = 0.14) in outcome between these groups for transplanted patients (5-year
DFS: 83 ± 14% and 33 ± 15%, respectively).
Conclusion: Age, leukocyte count and early response to treatment defined by the D21 bone
marrow response provide an accurate model for outcome prediction. The combination of available
tools such as minimal residual disease assessment with determination of these simple factors could
be useful for refining indications for BMT in the current era of tyrosine-kinase inhibitor-based
therapy.
Background
The philadelphia chromosome (Ph1) is detectable in 2%
to 5% of children with acute lymphoblastic leukemia
(ALL) [1,2]. The detection of a philadelphia chromosome
remains a major prognostic factor of induction failure.
Despite the steady improvement in the management of
ALL in children, Ph1-ALL is associated with high rates of
relapse or resistance to treatment [3-5]. This disease is het-
erogeneous in terms of clinical parameters such as leuko-
cyte count, age at diagnosis, and initial steroid response
[4,6]. A slow early response to conventional therapy has
also been reported as indicative of a poor prognosis [2].
Recent gene expression studies have identified a heteroge-
neous pattern of expression associated with BCR-ABL sta-
tus, which may be useful for developing novel prognostic
markers and future patient stratification procedures [7-9].
New therapeutic agents such as tyrosine kinase inhibitors
(imatinib and dasatinib) have been developed and yield
good results in adults with Ph1-ALL [10-12]. Little infor-
mation on the use of these drugs in children has been
reported; the identification of predictors of responsive-
ness to early conventional treatment may thus be benefi-
cial for the accurate stratification of children and for
improving outcome [13,14].
We studied the impact of the National Cancer Institute
(NCI) risk factors and steroid and early chemotherapy
responses in 36 children with untreated Ph1-ALL enrolled
in the FRALLE 93 trial between 1993 and 1999.
Methods
The FRALLE 93 trial was open to children aged 0 to 20
years with untreated ALL, not including those with L3 ALL
or Down's syndrome. Between June 1, 1993, and Decem-
ber 31, 1999, 1395 children were enrolled onto the
FRALLE 93 trial in 18 French pediatric centers and one
Belgian pediatric center. This study was approved by the
ethics committee of the hôpital Saint Louis, France
(accepted April 29, 1993). All patients, or their parents,
provided informed consent in accordance with the Decla-
ration of Helsinki. The diagnosis of ALL was based on
morphological, immunophenotypic and cytogenetic
analyses of bone marrow samples. From 1994, children
were systematically screened for four fusion transcripts
(TEL-AML1, BCR-ABL, E2A-PBX1, MLL-AF4).
Stratification and treatment
Patients carrying t(9,22) or BCR-ABL were assigned to the
very high risk group of the FRALLE 93 trial (Table 1) [5].
Patients received initial treatment comprising a pred-
nisone prophase and a triple-drug intrathecal injection.
Induction treatment then included prednisone, vincris-
tine, L-asparaginase, a 120 mg/m2 cumulative dose of
daunorubicin (increased to 160 mg/m2 after July 1996)
and two more triple-drug intrathecal injections. Treat-
ment was then stratified according to availability of an
HLA-matched sibling. Children with an HLA-matched
sibling received alternating courses of R3 (Cytarabine,
Etoposide, Dexamethasone) and COPADM (Vincristine,
Methotrexate, Doxorubicin, Cyclophosphamide, Pred-
nisone) therapy (for a total of 3 courses of treatment)
before an allogeneic bone marrow transplantation (Table
1). The remaining children with no sibling donors were
eligible for either autologous transplantation after six
courses of treatment (with graft harvesting carried out
after the fifth course of chemotherapy) or non genoiden-
tical allogeneic transplantation.
Treatment outcome was analyzed according to indicators
of early response to therapy. The prognostic value of per-
sistent lymphoblasts in blood sampled at day 8 and in
bone marrow at day 21–22 has been demonstrated in sev-
eral previous studies [15-17]. We also recently showed
that the persistence of lymphoblasts in bone marrow on
day 21 of four-drug induction was associated with a
higher risk of induction failure [5]. A good prednisone
response was defined as a blast count <1000/μl blood
after the first seven days on prednisone therapy (i.e. on
day 8) and one triple-drug intrathecal injection. A poorPage 2 of 8
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μl on day 8. A good early response to chemotherapy was
defined by a blast count fewer than 5% in bone marrow
smears on day 21 (M1) and a poor early chemotherapy
response by a blast count equal to or more than 5% (with
two categories: M2 = 5% to 25% and M3 = more than
25%). Complete remission (CR) was defined by no phys-
ical evidence of disease, no detectable leukemic blasts on
blood smears and less than 5% blasts on bone marrow
smears, active hematopoiesis and normal cerebrospinal
fluid.
Statistical analysis
Analysis was based on an intent-to-treat principle. CR
rates were compared using Fisher's exact test. Censored
endpoints were estimated by the non parametric Kaplan-
Meier method, and then compared by the log-rank test.
Multivariate analyses were carried out to define the set of
informative prognostic factors, using regression models
adapted to the endpoint, namely the logistic model for CR
rates, and Cox model for overall survival (OS) and event
free survival (EFS).
Type I error was fixed at 5%. All tests were two-tailed. Sta-
tistical analysis was performed using SAS 9.1 (SAS, Inc,
Cary, NC).
Results
Ph1 was detected by conventional cytogenetic analysis
(t(9;22) (q34;q11)) or a BCR-ABL rearrangement was
detected by reverse transcriptase-polymerase chain reac-
tion (RT-PCR) in 3% of the B-lineage ALL. Of the 36 Ph1-
ALL children, 30 had detectable t(9;22) and six were iden-
tified solely by the presence of the BCR-ABL fusion tran-
script. Thus, fusion transcript analysis was able to detect
nearly 17% more Ph1 patients than conventional karyo-
type. The m-BCR breakpoint was detected in 30 patients
and the M-BCR breakpoint in three others (3 patients
were identified solely by the detection of t(9;22)). At base-
line, median age was eight years [range: 0.70–19.5; Q1–
Q3: 4.35 to 12.35], male-to-female ratio was 1.1, median
leukocyte count was 29.1 × 109/l [Q1–Q3: 12.5–137] and
median hemoglobin was 9 g/dl [2.5–15]; four patients
displayed central nervous system defects (11.1%).
Complete remission was observed in 26 children (72%),
after a median of 40 days [range 32–51] consistent with
previous findings [2,4]. We did not find any differences
between the effects of including patients at two different
time periods (before or after July 1996) and the addition
of one dose of daunorubicin and two doses of asparagi-
nase (but the numbers of children within each group are
small) (Table 2).
Table 1: FRALLE 93 protocol schedule for very high risk patients
Phase Treatment Dose
Induction Vincristine 1.5 mg/m2 IV (max, 2 mg) on D8, D15, D22, D29
Prednisone 60 mg/m2/d PO on D1–8, 40 mg/m2/d on D8–28
Daunorubicin§ 40 mg/m2 IV on D8, D9, D10, D15
L-Asparaginase§ 10,000 U/m2 IM or IV on D20, D22, D24, D26, D29, D31, D33, D35
intrathecal therapy* before D4, D8, and D15
R3 course Cytarabine 2 g/m2 IV bid on D1–D2
Etoposide 150 mg/m2 IV on D3, D4, D5
Dexamethasone 20 mg/m2 PO on D2–D5
intrathecal therapy* D5
COPADM course Vincristine 1.5 mg/m2 (max, 2 mg) IV on D1
Methotrexate 8000 mg/m2 (24-hour IV infusion with leucovorin rescue) on D1
Doxorubicin 60 mg/m2 IV on D2
Cyclophosphamide 375 mg/m2 bid on D2–D3
Prednisone 60 mg/m2 PO on D1–D5
Stem-cell transplantation age >4 years: TBI 2 Gy bid on D-9 to D-7
age <4 years: Busulfan 30 mg/m2/6 hours PO on D-10 to D-7
All patients: Cytarabine 3 g/m2 bid on D-5 to D-4
Melphalan 140 mg/m2IV on D-2
Transplantation IV day 0
Maintenance after autologous transplantation 6-mercaptopurine Vincristine 75 mg/m2/d 2 years after complete remission 1.5 mg/m2 monthly for 
12 months
Abbreviations: PO, per os; IV, intravenous; IM, intramuscular; max, maximum; TBI, total body irradiation
§before July 1996: daunorubicin on D8, D15, and D22 and L-Asparaginase on D22, D24, D26, D29, D31, D33.
*Methotrexate, Cytarabine, and Depomedrol in doses based on patient age
Other post-induction regimen: no R3 or COPADM but 1 consolidation, 2 intensifications, and an interim phase over 36 weeks before 18 months of 
maintenance therapyPage 3 of 8
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but CR was observed in seven of them after one further
course of chemotherapy. The dexamethasone, cytarabine,
cyclophosphamide, etoposide, and idarubicin or dauno-
rubicin (CAZED) scheme was recommended as salvage
treatment in the FRALLE 93 protocol and thus was used in
five of these seven patients (amsacrine and cytarabine for
the 2 others) [5]. All seven children were then trans-
planted (2 matched related transplants, 4 matched unre-
lated transplants and one autologous transplantation);
outcomes are described in Figure 1. Of the other children
with CR observed after induction, five of the six children
with an HLA-matched sibling (MRD) received alternate
courses of R3 and COPADM treatment before allogeneic
bone marrow transplantation (one toxic death occurred
before graft). Eight children received an autologous trans-
plant, five a mismatched related transplant and two others
a matched unrelated transplant (MUD) (Figure 1). Five
other CR patients received a different post-induction regi-
men with intensified chemotherapy, including one con-
solidation, a double delayed intensification, and an
interim phase over 36 weeks before 18 months of mainte-
nance therapy.
Patient follow-up data were updated in February, 2007. In
an intention-to-treat analysis, 10 children remained in
CR1, giving a five-year disease-free survival (DFS) rate of
42.3% ± 9.7% and a five-year OS rate of 47.2% ± 8.3.
Leukemic relapse was the most common cause of adverse
events. Eleven children relapsed (no late relapse after 5
years) and five toxic deaths occurred (including one late
death from infection). No secondary malignancy was
observed.
Table 2 summarizes the main endpoints – CR, EFS and
survival – overall and as a function of the main patient
characteristics. Based on univariate analyses using a 5%
significance level for all endpoints, we identified two pre-
dictors of poor outcome: age ≥ 10 and white blood cells
(WBC) count >100,000/mm3. Response to chemotherapy
based on day 21 bone marrow was only predictive of
induction response (p = 0.0004). When incorporated
simultaneously in multivariate regression models, only
one predictive factor retained significant prognostic value
for a particular endpoint: M1 for CR, WBC count
>100,000/mm3 for EFS and age ≥ 10 for OS. Combining
the information of these three binary variables defined
two groups differing widely in terms of outcome: the 14
children with age<10, WBC<100,000/mm3 and M1
defined a group with a favorable prognosis (100% CR, 5-
yr EFS: 57%, 5-yr OS: 79%), whereas the remaining 22
children had poorer outcomes (55% CR, 5-yr EFS: 18%, 5-
yr OS: 27%) (p = 0.003, 0.002, and 0.003, respectively)
(Figure 2). These prognostic factors remain important in
the transplanted patients (equally divided in both
groups), even if significance is not reached due to the
Table 2: Outcome of the 36 children with philadelphia chromosome-positive acute lymphoblastic leukemia as a function of early 
characteristics
No patients No CR (%) p 5 yr-EFS p 5 yr-OS p
Whole cohort N = 36 26 (72%) 33.3 ± 7.9 47.2 ± 8.3
Inclusion period
< July, 1996 15 9 (60%) 20 ± 10 33 ± 12
> July, 1996 21 17 (81%) 0.26 43 ± 11 0.13 57 ± 11 0.31
Age (years)
<10 23 20 (87%) 48 ± 10 61 ± 10
≥ 10 13 6 (46%) 0.018 15 ± 10 0.01 23 ± 12 0.006
WBC (/mm3)
<50,000 21 17 (81%) 33 ± 10
≥ 50,000 15 9 (60%) 0.26 33 ± 12 0.54 0.91
<100,000 26 22 (85%) 42 ± 10 58 ± 10
≥ 100,000 10 4 (40%) 0.014 10 ± 9 0.003 20 ± 13 0.03
Response to steroid (+3 drug intra-thecal injection) at D8
poor (≥ 1000 blasts/mm3) 5 2 (40%) 20 ± 18 20 ± 18
good(<1000 blasts/mm3) 31 24 (77%) 0.12 35 ± 9 0.33 52 ± 9 0.19
Response to chemotherapy evaluated on D21
M1(≤ 5% blasts) 21 20 (95%) 43 ± 11 62 ± 11
M2+M3 (>5%–25% and >25% blasts) 15 6 (40%) 0.0004 20 ± 10 0.18 27 ± 11 0.06
Age, D21 response and WBC
Age<10 and D21 M1 and WBC count<100,000 14 14 (100%) 57 ± 13 79 ± 11
Others 22 12 (55%) 0.003 18 ± 8 0.002 27 ± 9 0.003
WBC = white blood cell; D = day; Response to steroid is evaluated in peripheral blood on day 8; Response to chemotherapy is evaluated in bone 
marrow on day 21Page 4 of 8
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with age<10, WBC<100,000/mm3 and M1 and 33 ± 15%
for the remaining patients) (p = 0.14).
Discussion and conclusion
This long-term study, carried out before the introduction
of imatinib mesylate, confirmed the prognostic value of
two major clinical factors (age, WBC count at diagnosis)
and identified the D21 marrow response as a powerful
complementary tool. We did not find prednisone
response to have statistically significant predictive value
for any endpoint studied, in contrast with earlier reports
[4,6]. This could be explained by the small sample size,
and the small number of poor prednisone responders (5
of 36; 14%). However, in our protocol the combination of
a three-drug intrathecal injection (methotrexate, cytarabin
and depomedrol) on day 1 with the 7 day prednisone
prophase prevents the comparison of our steroid-resist-
ance data to data in other studies using intrathecal meth-
otrexate.
Based on these three easily available indicators (age, WBC
at diagnosis and D21 response to chemotherapy), a pre-
dictive model can be built to define two subsets of chil-
dren that differ widely in terms of outcome. Such a model
should be further investigated in larger samples and in
ongoing pediatric trials integrating tyrosine-kinase inhib-
itors. The improved early responses observed with imat-
inib or dasatinib in adult studies, and similar, but very
preliminarily, results obtained in one pediatric study with
imatinib, now question the appropriate use of allogeneic
stem-cell transplantation [14,18]. Indeed, the COG
AALL0031 study showed that continuous administration
of imatinib given in combination with intensive chemo-
therapy backbone resulted in a significant improvement
in early EFS. More specifically cohort 5, who received 340
mg/m2 of imatinib for 280 days with chemotherapy only,
had a similar two years EFS as compared to the cohort of
patients who underwent stem cell transplantation (32
patients) either according to the protocol (MRD-21
patients) or from MUD (11 patients)[14]. The combina-
tion of available tools, including minimal residual disease
flowchart of the FRALLE 93 trial for philadelphia chromosome-positive ALLFigure 1
flowchart of the FRALLE 93 trial for philadelphia chromosome-positive ALL. Children with ALL were allocated to 
very high risk group as soon as a t(9;22) or BCR-ABL rearrangement was detected. Post-induction treatment was then stratified 
according to availability of an HLA-matched sibling. CR1 = first complete remission; MRD = matched related donor; MUD = 
matched unrelated donor; MMRD = mismatched related donor.Page 5 of 8
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could be useful for refining the indications for bone mar-
row transplantation [19-22]. Thus, if the long term fol-
low-up of the AALL0031 non randomized study was
confirmed, good risk patients could be spared by trans-
plantation.
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